title: Hepatic extramedullary disease in multiple myeloma with 17p deletion.
authors.affiliation: Department of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan. Electronic address: mise@chiba-cc.jp.
authors.forename: Mikiko
authors.initials: M
authors.lastname: Ise
authors.affiliation: Department of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Tsujimura
authors.affiliation: Department of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.
authors.forename: Chikara
authors.initials: C
authors.lastname: Sakai
authors.affiliation: Department of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.
authors.forename: Kyoya
authors.initials: K
authors.lastname: Kumagai
mesh_terms: D000782:Aneuploidy; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D002886:Chromosomes, Human, Pair 17 / Q000648:ultrastructure*; D002999:Clone Cells / Q000737:chemistry / Q000648:ultrastructure; D003907:Dexamethasone / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D017353:Gene Deletion; D016158:Genes, p53; D006801:Humans; D033162:Incidental Findings; D000077269:Lenalidomide; D008099:Liver / Q000473:pathology*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000737:chemistry / Q000150:complications / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D009363:Neoplasm Proteins / Q000032:analysis; D009378:Neoplasms, Multiple Primary; D010014:Osteolysis / Q000175:diagnosis / Q000209:etiology; D061988:Proteasome Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D014594:Uterine Neoplasms / Q000601:surgery
chemical_list: D020533:Angiogenesis Inhibitors; D001897:Boronic Acids; D009363:Neoplasm Proteins; D061988:Proteasome Inhibitors; D011719:Pyrazines; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide
keywords: Aggressive; Liver; Nodular; Second malignancy; p53